Literature DB >> 6351948

Drug resistance and cancer chemotherapy strategy in breast cancer.

J H Goldie.   

Abstract

Evidence exists that spontaneous mutations to drug resistance are a major obstacle to chemotherapeutic cure in both experimental and clinical neoplasms. Analysis of this phenomenon indicates that certain treatment strategies may be more effective in circumventing resistance. Initiation of adjuvant chemotherapy at the earliest time feasible is such an approach. The use of combinations of non-cross resistant agents is another. These methods should reduce the probability that drug-resistant cells will be present at the time treatment is started, and in theory should produce improved therapeutic results.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6351948     DOI: 10.1007/bf01803555

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  23 in total

1.  Origin of the resistance of leukaemic cells to folic acid antagonists.

Authors:  L W LAW
Journal:  Nature       Date:  1952-04-12       Impact factor: 49.962

2.  Combination chemotherapy in disseminated testicular cancer: the Indiana University experience.

Authors:  L H Einhorn; J P Donohue
Journal:  Semin Oncol       Date:  1979-03       Impact factor: 4.929

3.  Rationale for the use of alternating non-cross-resistant chemotherapy.

Authors:  J H Goldie; A J Coldman; G A Gudauskas
Journal:  Cancer Treat Rep       Date:  1982-03

4.  Combined endocrine therapy and chemotherapy of mouse mammary tumors.

Authors:  M Sluyser; C C de Goeij; S G Evers
Journal:  Eur J Cancer       Date:  1981-02       Impact factor: 9.162

5.  Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer.

Authors:  A J Suarez; D L Lamm; H M Radwin; M Sarosdy; G Clark; C K Osborne
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  Surgical adjuvant chemotherapy: results with one short course with cyclophosphamide after mastectomy for breast cancer.

Authors:  R Nissen-Meyer; K Kjellgren; K Malmio; B Månsson; T Norin
Journal:  Cancer       Date:  1978-06       Impact factor: 6.860

7.  Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial.

Authors:  J H Glick; R H Creech; S Torri; C Holroyde; H Brodovsky; R B Catalano; M Varano
Journal:  Cancer       Date:  1980-02-15       Impact factor: 6.860

8.  Prognostic factors in metastatic breast cancer treated with combination chemotherapy.

Authors:  K D Swenerton; S S Legha; T Smith; G N Hortobagyi; E A Gehan; H Y Yap; J U Gutterman; G R Blumenschein
Journal:  Cancer Res       Date:  1979-05       Impact factor: 12.701

9.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

Authors:  J H Goldie; A J Coldman
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

10.  Risk and prognostic factors in trophoblastic neoplasia.

Authors:  K D Bagshawe
Journal:  Cancer       Date:  1976-09       Impact factor: 6.860

View more
  5 in total

1.  New strategies in cancer chemotherapy.

Authors:  G Bonadonna
Journal:  Cell Biophys       Date:  1986-12

Review 2.  Implications of tumor progression on clinical oncology.

Authors:  D R Welch; S P Tomasovic
Journal:  Clin Exp Metastasis       Date:  1985 Jul-Sep       Impact factor: 5.150

Review 3.  Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches.

Authors:  Muhammad Tufail; Jia Cui; Changxin Wu
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

4.  Mechanisms of Drug Resistance and Use of Nanoparticle Delivery to Overcome Resistance in Breast Cancers.

Authors:  Huseyin Beyaz; Hasan Uludag; Doga Kavaz; Nahit Rizaner
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Therapy's Shadow: A Short History of the Study of Resistance to Cancer Chemotherapy.

Authors:  Peter Keating; Alberto Cambrosio; Nicole C Nelson; Andrei Mogoutov; Jean-Philippe Cointet
Journal:  Front Pharmacol       Date:  2013-05-07       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.